Risk of Dementia After Initiation of Sodium-Glucose Cotransporter-2 Inhibitors Versus Dipeptidyl Peptidase-4 Inhibitors in Adults Aged 40-69 years with type 2 Diabetes:Population Based Cohort Study
BMJ doi:10.1136/BMJ-2024-07945, Shin,A., et al, 2024
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Neurol 103:e209805, Kim,H.K.,et al, 2024
Vitamin B12 Deficiency:NICE Guideline Summary
BMJ 385:q1019, q1262, Sands,T.,et al, 2024
Proton Pump Inhibitor and Histamine 2 Receptor Antagonist Use and Vitamin B12 Deficiency
JAMA 310:2435-2442, Lam, J.R.,et al, 2013
JC Virus Infection of the Brain
AJNR 31:1564-1576, Bag,A.K.,et al, 2010
Hearing Improvement After Bevacizumab in Patients with Neurofibromatosis Type 2
NEJM 361:358-367, Plotkin,S.R.,et al, 2009
Daclizumab Phase II Trial in Relapsing and Remitting Multiple Sclerosis
Neurol 69:785-789, Rose,J.W.,et al, 2007
Coxibs and Alzheimers Disease: Should They Stay or Should They Go?
Ann Neurol 59:219-228, Firuzi,O. &Pratico,D., 2006
Terminating Migraine with Allodynia and Ongoing Central Sensitization Using Parenteral Administration of COX1/COX2 Inhibitors
Headache 45:850-861, Jakubowski,M.,et al, 2005
Aseptic Meningitis Associated with Rofecoxib
Arch Int Med 162:713-715, Bonnel,R.A.,et al, 2002
HIV-associated Neurologic Disease Incidence Changes: Multicenter AIDS Cohort Study, 1990-1998
Neurol 56:257-260, Sacktor,N.,et al, 2001
A 47-Year-Old Woman with Tension-Type Headaches
JAMA 286:960-966, Welch,K.M.A., 2001
Incidence and Prevalence of Neurological Disorders Associated with HIV Since the Introduction of Highly Active Antiretroviral Therapy (HAART)
JNNP 69:376-380, Maschke,M. et al, 2000
Adverse Effects of Antiretroviral Therapy
Lancet 356:1423-1430, Carr,A. &Cooper, D.A., 2000
HAART Improves Prognosis in HIV-Associated Progressive Multifocal Leukoencephalopathy
Neurol 52:623-625,440, Clifford,D.B.,et al, 1999
Regress of HIV Enceph & Basal Ganglia Signal Intensity Abnor MRI in AIDS after Protease Inhibitor
Neuroradiology 206:491-498, Filippi,C.G.,et al, 1998
HIV-Protease Inhibitors
NEJM 338:1281-1292, Flexner,C., 1998
Lipodystrophy Associated with an HIV-Protease Inhibitor
NEJM 339:1296, Carr,A.&Cooper,D.A., 1998
Buffalo Hump in a Patient with the Acquired Immunodeficiency Syndrome
NEJM 339:1297, Aboulafia,D.M.&Bundow,D., 1998
HIV-1 Protease Inhibitors
JAMA 227:145-149, Deeks,S.J.,et al, 1997
HIV Infection-1
BMJ 314:487-491, 579-5831997., Cohn,J.A., 1997
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
JAMA Neurol 92:19-29, Salloway,S.,et al, 2025
Inebilizumab for Treatment of IgG4-Related Disease
NEJM 392:1168-1177, Stone,J.H.,et al, 2025
Beyond Glucocorticoids for IgG4-Related Disease
NEJM 392:1232-1233, Spiera,R., 2025
"Innumerable" lesion burden on brain MRI - a diagnostic approach
Diagnosis doi.org/10.1515/dx- 2025-2029, Finelli,P.F., 2025
Progress Toward Mitigating Disability Progression in Multiple Sclerosis
NEJM 392:1966-1968, Calabresi,P.A., 2025
Upadacitinib - An Up-and-Comer for Treatment of Giant-Cell Arteritis
NEJM 392:2062-2064, Koster,M.J. & Warrington,K.J., 2025
A 69-Year-Old Woman with Ophthalmoplegia
Neurol 104:e213763, Yu, H & Frey, J, 2025
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis
NEJM 392:2309-2320, Nowak,R.J.,et al, 2025
Myasthenia Gravis - Redemption for B-Cell Depletion
NEJM 392:2382-2384, Wolfe,G.I. & Shelly,S., 2025
Efficacy and Safety of Selimetinib in Adults with Neurofibromatosis Type 1 and Symptomatic, Inoperable Plexiform Neurofibromas (KOMET): A Multcentre, International, Randomised Placebo-Controlled, Parallel, Double-Blind, Phase 3 Study
Lancet 405:2217-2230, Chen,A.P.,et al, 2025
Efficacy and Safety of Ofatumumab Treatment for Anti-NMDA Receptor Autoimmune Encephalitis (OFF-AE): A Prospective, Multicenter Cohort Study
Ann Neurol 98:80-92, Guo,K.,et al, 2025
Collaboration on the Optimal Timing of Anticoagulation after Ischaemic Stroke and Atrial Fibrillation:A Systematic Review and Prospective Individual Participant Data Meta-Analysis of Randomised Controlled Trials (CATALYST)
Lancet 406:43-51, Dehbi,K-M.,et al, 2025
New Treatments for Migraine: CGRP Monoclonal Antibodies, Gepants, and Ditans
BMJ 390:e085564, Burch, R. & Rittenberg, E., 2025
An Unusual Etiology of Lumbosacral Plexopathy in a Patient with HIV
Neurol 103:e209930, Madduluri,B.,et al, 2024
Thrombolysis After Dabigatran Reversal for Acute Ischemic Stroke
Neurol 103:e209862, Theodorou,A.,et al, 2024
Optimal Timing of Anticoagulation after Acute Ischaemic Stroke with Atrial Fibrillation (OPTIMAS): A Multicentre, Blinded-Endpoint, Phase 4, Randomised Controlled Trial
Lancet 404:1731-1741, Werring,D.J.,et al, 2024
Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine, A Phase 4, Randomized, Placebo-Controlled Trial
JAMA Neurol 81:1140-1149, Tepper,S.J.,et al, 2024
Apixaban vs Aspirin in Patients with Cancer and Cryptogenic Stroke A Post Hoc Analysis of the ARCADIA Randomized Clinical Trial
JAMA Neurol 81:957-965, Navi,B.B.,et al, 2024
Advances in Cerebral Venous Thrombosis
Stroke 55:2169-2172, deSousa,D.A. & Neto,L.L., 2024
Clinical Presentation, Management, and Outcome in Neurolymphomatosis, A Systematic Review
Neurol 103:e209698, Kaulen.L.D.,et al, 2024
Lecanemab for Alzheimer Disease, Is It Worth It?
Neurol 102:e209265, Nelson,S.E. & Lopez,O.L., 2024
Magnetic Resonance Imaging Characteristics of LGl1-Antibody and CASPR2-Antibody Encephalitis
JAMA Neurol 81:525-533, Kelly,Mark J., et al, 2024
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage
NEJM 390:1745-1755, 1815, Connolly,S.J.,et al, 2024
Mechanical Thrombectomy in Anticoagulated Patients with Acute Ischemic Stroke, A Meta-Analysis
Neurologist 29:194-203, Zhang,H.L.,et al, 2024
Tenecteplase Versus Standard of Care for Minor Ischaemic Stroke with Proven Occlusion (TEMPO-2): A Randomised, Open Label, Phase 3 Superiority Trial
Lancet 403:2597-2605, Coutts,S.B.,et al, 2024
Leptomeningitis with Communicating Hydrocephalus in an Immunocompromised Patient with Disseminated Sporotrichosis
Neurol 103:e209586, Taborda,M.H.,et al, 2024
Inhibition of CD40L with Frexalimab in Multiple Sclerosis
NEJM 390:589-600, 662, Vermersch,P.,et al, 2024